Webinar

Living kidney donation: Everything you need to know

surgeon holding plastic kidney
There is no question that for most people, kidney transplant is considered the best treatment option for kidney failure. Receiving a new kidney can help you live a longer and healthier life. When considering a kidney transplant, one of the biggest questions a recipient may have is where that kidney will come from – whether from a living or deceased donor.

In recognition of National Donate Life Month, this month's webinar will focus on living kidney donation. Kidney transplant is often a life-changing event for both a recipient and their donor, and anyone considering a kidney transplant or becoming a living donor should know all the facts about the process to make the most informed decisions about their health.

Dr. Melancon, Chief Surgeon at George Washington Transplant Institute will join us to discuss the living donation process and clear up commonly held myths and misunderstandings about being a living kidney donor.

Topics you can expect Dr. Melancon to address include:

  • An overview of the living kidney donation process
  • Common concerns held by people who are considering donating a kidney (for example, whether women who donate can have children after surgery)
  • How kidney donation affects the health of the donor
  • Financial considerations for living donors

View additional questions and answers from the live webinar.

 

Speaker

dr-melancon

Dr. Keith Melancon

Dr. Melancon is currently the Director of the George Washington Transplant Institute and the Medical Director of The Ron and Joy Paul Kidney Center at George Washington University Medical School. Dr. Melancon is a Professor of Surgery whose specialties include kidney, pancreas and liver transplantation, as well as laparoscopic kidney donor nephrectomy. His research interests have centered upon increasing access to health care for minority patients, particularly in the field of organ transplantation.

Dr. Melancon has spent his career trying to improve outcomes for the hardest to transplant patients and therefore has been an advocate for ABO incompatible organ transplantation, paired kidney exchanges, and immune system desensitization strategies. Recently, Dr. Melancon and his team were the first ever to perform a fully ABO incompatible deceased donor kidney transplantation as well as a fully ABO incompatible living donor kidney transplantation in an individual with HIV infection.

He hopes that with novel immunosuppression protocols that organ transplants will begin to last for the life time of the patient and that true transplant tolerance can be achieved in the near future.